Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) PT at $50.25

TG Therapeutics, Inc. (NASDAQ:TGTX) has earned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $50.25.

Several analysts have recently weighed in on the stock. B. Riley raised shares of TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday. HC Wainwright initiated coverage on TG Therapeutics in a research report on Monday, October 6th. They issued a “buy” rating and a $60.00 price objective for the company. JPMorgan Chase & Co. raised their target price on TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Finally, Wall Street Zen raised TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th.

Insider Activity

In other TG Therapeutics news, Director Yann Echelard sold 5,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $32.57, for a total value of $162,850.00. Following the transaction, the director owned 223,816 shares of the company’s stock, valued at $7,289,687.12. This represents a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Sagar Lonial sold 20,852 shares of the stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the transaction, the director directly owned 94,061 shares of the company’s stock, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 10.64% of the stock is currently owned by insiders.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds have recently made changes to their positions in TGTX. State Street Corp raised its position in TG Therapeutics by 2.5% in the second quarter. State Street Corp now owns 7,618,238 shares of the biopharmaceutical company’s stock valued at $274,180,000 after purchasing an additional 184,339 shares during the period. Geode Capital Management LLC grew its stake in shares of TG Therapeutics by 6.3% in the second quarter. Geode Capital Management LLC now owns 3,490,457 shares of the biopharmaceutical company’s stock valued at $126,033,000 after buying an additional 207,890 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of TG Therapeutics by 21.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after buying an additional 345,059 shares during the period. Hood River Capital Management LLC raised its holdings in shares of TG Therapeutics by 0.7% in the 2nd quarter. Hood River Capital Management LLC now owns 1,567,506 shares of the biopharmaceutical company’s stock valued at $56,415,000 after buying an additional 11,018 shares during the period. Finally, Wellington Management Group LLP lifted its stake in TG Therapeutics by 1,809.9% during the 1st quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company’s stock worth $47,830,000 after acquiring an additional 1,149,526 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Up 3.2%

NASDAQ TGTX opened at $31.61 on Monday. The business’s fifty day simple moving average is $33.63 and its 200-day simple moving average is $33.85. The company has a quick ratio of 2.89, a current ratio of 3.82 and a debt-to-equity ratio of 0.40. The firm has a market cap of $5.02 billion, a PE ratio of 11.37 and a beta of 2.01. TG Therapeutics has a 52 week low of $25.28 and a 52 week high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $2.19. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The firm had revenue of $161.71 million during the quarter, compared to analyst estimates of $152.12 million. During the same quarter in the prior year, the firm posted $0.02 earnings per share. TG Therapeutics’s quarterly revenue was up 92.7% on a year-over-year basis. As a group, equities analysts anticipate that TG Therapeutics will post 0.08 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.